Schering-Plough Reports Financial Results for 2009 Seco...(78 (14%) 128 152 (16%) ...)

Date:7/21/2009

78 (14%) 128 152 (16%) INTRON 67 61 10% 121 116 4% PROVENTIL / ALBUTEROL 56 38 46% 110 89 24% ASMANEX 54 48 12% 103 91 14% SUBUTEX / SUBOXONE 52 62 (15%) 102 115 (12%) REMERON 50 61 (18%) 100 129 (22%) ELOCON 45 47 (4%) 87 92 (6%) CERAZETTE 46 49 (6%) 85 93 (8%) NOXAFIL 43 38 14% 82 72 15% IMPLANON 43 44 (1%) 80 82 (2%) MERCILON 33 47 (30%) 68 90 (25%) LIVIAL 39 50 (22%) 72 95 (24%) MARVELON 36 40 (9%) 68 77 (13%) ZEMURON 33 67 (51%) 65 130 (50%) FORADIL 25 25 (1%) 48 51 (4%) Other Pharmaceuticals 735 755 (3%) 1,396 1,458 (4%) ANIMAL HEALTH 677 818 (17%) 1,307 1,540 (15%) CONSUMER HEALTH CARE 381 401 (5%) 765 778 (2%) OTC 184 181 2% 416 389 7% OTC CLARITIN 108 120 (10%) 257 258 - MiraLAX 36 28 30% 73 54 36% Other OTC 40 33 22% 86 77 11% Foot Care 101 105 (4%) 174 190 (8%) Sun Care 96 115 (17%) 175 199 (12%) -- --- --- --- CONSOLIDATED GAAP NET SALES $4,647 $4,921 (6%) $9,040 $9,57
'/>"/>

SOURCE Schering-Plough Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma